JPRN-UMIN000003274已完成2 期
A phase II trial of gefitinib and concurrent radiation therapy for locally advanced non-small cell lung cancer patients harboring sensitive EGFR mutations. - A phase II trial of gefitinib and concurrent radiation therapy for locally advanced non-small cell lung cancer patients harboring sensitive EGFR mutations.
ational Hospital Organization0 个研究点目标入组 15 人开始时间: 2010年3月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients with active severe infections 2.Significant interstitial pneumonitis , pulmonary fibrosis on Chest CT 3.Contralateral hilar lymph node metastasis 4.Patietns with ileus 5.Patients with uncontrollable diarrhea 6.The presence of other concomitant cancers 7.Serious allergy history 8.Patients with total gastrectomy 9.Heavy smoking habit: (the number of cigarettes smoked daily) x (smoking period)> 400 10.Tumor infiltrating great vessels clearly 11.Patients harboring T790M mutation 12.Inappropriate patients for this study judged by the physicians
研究者
相似试验
已完成
不适用
A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFRnon-small-cell lung cancerJPRN-UMIN000004296Okayama Lung Cancer Study Group42
招募中
1 期
A Phase I/II trial to evaluate gefitinib and concurrent postoperative chemoradiation in patients with advanced resectable head and neck cancerACTRN12605000510640peter maccallum Cancer Centre70
已完成
2 期
Randomized phase II study of continuous gefitinib plus chemotherapy versus alternation of gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive EGFR mutations (NEJ005/TCOG0902)on-small cell lung cancer with EGFR mutations (non-squamous histology)JPRN-UMIN000002789orth East Japan Study Group/The Tokyo Cooperative Oncology Group80
已完成
不适用
A phase II study of gefitinib as first-line treatment for elderly patients with advanced lung adenocarcinoma who have active EGFR mutationslung adenocarcinomaJPRN-UMIN000002783agano lung cancer study meeting15
招募中
2 期
Randomised phase 2 trial of gefitinib plus bevacizumab vs gefitinib alone in patients with EGFR mutant non-squamous non small cell lung cancenon small cell lung cancerJPRN-UMIN000013586BAGEL study group90